McKesson — Feb 5, 2025 release

This strategy has enabled our strong results and is a foundation for balanced growth and value creation. Based on our third quarter performance, we are raising and narrowing our guidance range for fiscal 2025 Adjusted Earnings per Diluted Share to $32.55 to $32.95." Mr. Tyler added, "We are also pleased to announce the signing of a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, in support of our leadership in community practice management and specialty solutions. With this transaction, we intend to develop a leading platform for retinal care, delivering differentiated solutions and value across providers, biopharma partners, and patients. McKesson has a long track record of leading practice management and clinical research outcomes with our differentiated Oncology platform, and we are excited to leverage this expertise to serve the high-growth area of retina and ophthalmology. We are executing against our strategy and expanding our suite of solutions to continue to pursue our purpose of advancing health outcomes for all." 1 See below under "Fiscal 2025 Outlook" for full explanation Fiscal 2025 Third Quarter Result Summary Third Quarter Year-to-Date ($ in millions, except per share amounts) FY25 FY24 Change FY25 FY24 Change Revenues $ 95,294  $ 80,898  18  % $ 268,228  $ 232,596  15  % Operating Profit 1,293  676  91  3,064  2,791  10  Adjusted Operating Profit 2 1,463  1,261  16  4,059  3,639  12  Net incom